Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
FATE Stock Chart & Stats
$0.96
-$0.10(-5.71%)
At close: 4:00 PM EST
$0.96
-$0.10(-5.71%)
Day’s Range― - ―
52-Week Range$0.66 - $2.31
Previous CloseN/A
Volume630.90K
Average Volume (3M)2.28M
Market Cap
$125.73M
Enterprise Value$13.76M
Total Cash (Recent Filing)$215.42M
Total Debt (Recent Filing)$79.25M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Mar 02, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding115,352,290
10 Day Avg. Volume1,752,374
30 Day Avg. Volume2,275,470
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.59
Price to Sales (P/S)13.76
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit1.93
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$5.29Price Target Upside451.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst is upgrading recommendation to Buy from Neutral, while instituting a 12-month price target of $5.
Clinical Trials ProgressFate is expanding into additional indications and increasing its footprint through planned trials in the UK and EU.
Regulatory ApprovalsFate has received regulatory approval from both the UK's MHRA and the EU's EMA to begin clinical trials of FT819 for autoimmune diseases.
Bears Say
Clinical Efficacy RisksRisks include failure to demonstrate a meaningful clinical efficacy advantage with FT819 relative to other allogeneic and autologous CAR-T approaches.
Durability ConcernsRecent update showed mixed durability relating to B-cell aplasia, especially in patients who received no conditioning.
Safety And Immunogenicity ConcernsRisks include unexpected safety and immunogenicity concerns, partnership-related risks, and negative reactions from regulatory agencies.
Fate Therapeutics News
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $0.66 and its highest was $2.31 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is $125.73M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Mar 02, 2026 which is in 74 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.292 by $0.022.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 115,352,290 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.292. Following the earnings report the stock price went down -4.808%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in FATE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.29 (451.04% Upside)
$5.29 (451.04% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 300.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-54.95%
12-Months-Change
Fundamentals
Return on Equity
-52.35%
Trailing 12-Months
Asset Growth
-30.57%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. is a biotechnology company focused on developing innovative cell-based therapies for cancer and immune disorders. The company operates primarily in the regenerative medicine sector, leveraging its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cellular therapies that are designed to enhance the immune system's ability to combat diseases. Key products in their pipeline include various engineered cell therapies intended for the treatment of hematologic malignancies and solid tumors, as well as applications in hematopoietic cell transplantation and autoimmune diseases.
FATE Stock 12 Month Forecast
Average Price Target
$5.29
▲(451.04% Upside)
Technical Analysis
Compugen
―
Oncolytics Biotech
―
Oncolytics Biotech
―
Cardiff Oncology
―
Nkarta
―
Shattuck Labs
―
Ownership Overview
13.01% Insiders
13.39% Mutual Funds
27.83% Other Institutional Investors
35.64% Public Companies and
Individual Investors